Log In
BCIQ
Print this Print this
 

Listeria monocytogenes/PSA (Lm-LLO-PSA) vaccine (ADXS-PSA) (formerly ADXS31-142)

Also known as: formerly Lovaxin P

  Manage Alerts
Collapse Summary General Information
Company Advaxis Inc.
DescriptionLive attenuated Listeria monocytogenes immunotherapy targeting prostate-specific antigen (KLK3; PSA)
Molecular Target Prostate-specific antigen (KLK3) (PSA)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC); Treat prostate cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$38.0M

0

$33.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today